1194 results about "Recombinant expression" patented technology

The invention provides humanized recombinant XVII collagen for promoting hair follicle stem cell repair and resisting aging as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The humanized recombinant XVII type collagen comprises polypeptide derived from the XVII type collagen or repeated protein formed by N times of repeated series connection of the polypeptide serving as a unit, n is an integer from 2 to 4; the polypeptide derived from the XVII type collagen comprises a polypeptide A and / or a polypeptide B; the amino acid sequence of the A polypeptide is as shown in SEQ ID NO: 1; and the amino acid sequence of the B polypeptide is as shown in SEQ ID NO: 2. The humanized recombinant XVII type collagen not only can be massively and stably recombined and expressed, but also has cell adhesion activity, cell proliferation promotion activity, cell migration promotion activity and excellent hair follicle repair and regeneration promotion activity, and has no sensitization side effect. The invention provides a new way for preparing collagen products with rich functions.

The invention discloses a PgEGY3 gene for improving cold resistance of pennisetum alopecuroides and increasing fresh weight of leaves and application of the PgEGY3 gene, and relates to the technical field of genetic engineering, and the nucleotide sequence of the PgEGY3 gene of the pennisetum alopecuroides is shown as SEQ ID NO.1. The invention also discloses a protein coded by the Pennisetum alopecuroides PgEGY3 gene. The invention also discloses a recombinant expression vector and a recombinant host cell comprising the Pennisetum alopecuroides PgEGY3 gene. The invention also discloses application of the PgEGY3 gene, a recombinant expression vector and a recombinant host cell in improving cold resistance and biomass of pennisetum alopecuroides. It is verified that the Pennisetum alopecuroides PgEGY3 gene can improve the cold resistance of plants, and the growth state of the plants under cold stress is remarkably improved through overexpression of the PgEGY3 gene.

The invention relates to the field of gene engineering for enhancing the cold resistance of plants, and relates to a recombinant expression vector, a recombinant strain and a primer pair of a pennisetum purpureum PpMYB2 gene, a method for improving the cold resistance of the plants and application of related materials in improving the cold resistance of the plants. One purpose of the invention is to provide application of the Pennisetum purpureum PpMYB2 gene and related materials thereof in improving the cold resistance of the plant, the amino acid sequence of the encoding protein of the Pennisetum purpureum PpMYB2 gene is as shown in SEQ ID NO.1, and the plant is arabidopsis thaliana or Pennisetum purpureum. Under the background that extreme low temperature events caused by global climate change are increasingly frequent, the cold resistance enhancing technology provided by the invention has important significance on guaranteeing the stability of agricultural production and reducing loss caused by low temperature. Through overexpression of the gene PpMYB2, the adaptability of perennial pennisetum purpureum to low-temperature stress can be remarkably improved, so that the planting range of perennial pennisetum purpureum is expanded to regions with lower temperature, and the survival and growth performance in different ecological environments is enhanced.

The invention discloses humanized III-type collagen as well as a preparation method and application thereof, and belongs to the technical field of bioengineering. According to the method, firstly, on the basis of an original humanized III-type collagen gene, cell adhesion activity is taken as an evaluation index, a better cell adhesion sequence is screened out and spliced and integrated with the original collagen gene, and brand-new humanized III-type collagen is obtained. And constructing a recombinant expression vector of the humanized III type collagen containing the adhesion sequence by taking the probiotic EcN as a host cell, and introducing the recombinant expression vector into the EcN to obtain a strain of functional recombinant probiotic. Compared with a traditional escherichia coli engineering bacterium BL21 (DE3), the recombinant probiotics have good cell adhesion activity while efficiently expressing the humanized type III collagen, the bacterial endotoxin content of the recombinant humanized type III collagen obtained through purification meets the industrial standard, and the recombinant probiotics have good application prospects. The purification cost caused by industrial removal of endotoxin can be avoided, so that the production cost is reduced, and the method has a good application prospect.

The invention discloses SGNH family esterase SH2 screened in a Tibetan hot spring environment and application of the SGNH family esterase SH2, and belongs to the technical field of gene engineering. According to the invention, a new SGNH family esterase gene is screened from a Tibetan hot spring environment, and recombinant expression is realized in escherichia coli. The recombinant esterase prepared by the invention has the characteristics of thermal stability, salt resistance, organic solvent resistance and the like, can be safely applied to tooth whitening or skin exfoliating products, avoids damage of traditional chemical bleaching agents to enamel, and has important application value in the fields of daily chemicals, medicines, food processing and the like.

The present invention relates to a recombinant human type IV collagen and a preparation method therefor, which belong to the technical field of bioengineering. A recombinant human type IV collagen is designed on the basis of a partial sequence in an α2 chain of human type-IV collagen, and DNA encoding of the protein is ligated into an expression vector to construct a recombinant expression vector; then the recombinant expression vector is transformed into competent Escherichia coli cells, and a recombinant expression plasmid is extracted; after the plasmid is linearized, the linearized plasmid is transformed into an engineered strain HCPB-PPKEX2 to obtain a recombinant engineered strain; and the engineered strain is cultured, the expression of a target protein is induced, and the target protein is purified and identified. It is further demonstrated experimentally that the collagen can be completely cleaved by Kex2, Ste13 and CPB enzymes and efficiently secreted and expressed extracellularly, and the obtained sequence is completely consistent with a theoretical sequence. It is also verified experimentally that the recombinant collagen has a cell adhesion activity and a cell migration-promoting activity. The method avoids the risk of residual exogenous proteins, shortens the time and reduces the cost of the subsequent purification process, and thus has a relatively high safety and application value.

The invention discloses application of scylla serrata antibacterial peptide Scycin in preparation of an anti-inflammatory composition and a preparation method of the scylla serrata antibacterial peptide Scycin. The nucleotide sequence of the scylla serrata antibacterial peptide Scycin is shown as SEQ ID NO.01. The invention further discloses a preparation method of the scylla serrata antibacterial peptide Scycin. In an LPS (lipopolysaccharide)-induced RAW 264.7 macrophage inflammation model, the recombinant expression plasmid vector containing the scylla antibacterial peptide Scin remarkably inhibits an inflammation cascade reaction by down-regulating expression of proinflammatory factors such as TNF-alpha (tumor necrosis factor-alpha) and IL-6 (interleukin-6), the anti-inflammatory effect of the recombinant expression plasmid vector is equivalent to that of a mesalazine positive control group, and obvious cytotoxicity is not observed.

The invention relates to the technical field of biomedicine, discloses mutant photo-induced ion channel ChR-2 protein, and further discloses a nucleic acid construct, an expression vector, a cell, related application and a computer model. The light-sensitive channel ChR2 protein mutant obtained by the invention has stronger light current, and the light-sensitive capability of the light-sensitive channel ChR2 protein mutant is at least improved by 100 times; besides, the invention also obtains a nucleotide sequence for coding the light-sensitive channel ChR2 protein mutant, constructs a recombinant expression vector, and obtains the light-sensitive channel ChR2 protein with higher expression quantity and stronger light sensitivity, and the light-sensitive channel ChR2 protein is very suitable for expression in cells of mammals (especially human); according to the invention, the rhodopsin in different channels is systematically studied by modifying the position G224 in the helix 6 of seven transmembrane helix motifs, which proves that the mutation of the position G224 in the helix 6 in WT ChR2 accelerates the photosensitivity of the channels, and the considered position is homologous in the helix 6 of the rhodopsin in different channels.

The invention discloses a novel biosynthesis path for producing 3 '-phosphoadenosine-5'-phosphosulfuric acid and application, and belongs to the technical field of bioengineering. According to the invention, through recombinant expression and purification of ribose kinase, ribose phosphate pyrophosphate kinase, ribose phosphate transferase, adenine thiotransferase, adenosine phosphate sulfate kinase and polyphosphate kinase 2, a six-enzyme cascade reaction taking ribose and adenosine as substrates in vitro is constructed, the molar conversion rate reaches 22.85%, and the escherichia coli and bacillus subtilis PAPS cell factory can be used for preparing the recombinant ribose phosphate pyrophosphate kinase, the ribose phosphate transferase, the adenine thiotransferase, the adenosine phosphate sulfate kinase and the polyphosphate kinase 2. The yield of PAPS in a 5-L fermentation tank reaches 7.60 g / L and 5.03 g / L respectively. The PAPS synthesis route provided by the invention provides an extensible, economical and efficient solution for the production of sulfated compounds.

The invention discloses a double-structural-domain recombinant human fibronectin, the sequence of which is shown as SEQ ID NO.3, and the double-structural-domain recombinant human fibronectin is formed by fusing a collagen binding structural domain and a cell binding structural domain of human fibronectin. The invention also provides a recombinant expression vector containing the protein coding gene and a host cell. The protein is efficiently expressed through eukaryotic cells and engineering bacteria escherichia coli, and a fermentation and purification process suitable for an industrial scale is established in a matched manner. Functional experiments prove that compared with commercially available fibronectin products with a single structural domain, the double-structural domain recombinant human chemical fibronectin disclosed by the invention can remarkably promote proliferation, migration, adhesion and differentiation activity of human skin fibroblasts, and has wide application potential in the fields of skin repair, skincare and biomedical materials.

The invention discloses a method for promoting lactobacillus activity enhancement, which comprises the following steps: S1, amplifying a target gene corresponding to an LPxTG structural protein, and amplifying a target gene corresponding to a signal peptide; s2, obtaining a target gene connected with the LPxTG structure and the signal peptide; s3, connecting the target gene obtained in the step S2 with a plasmid gene sequence to construct a recombinant expression vector; s4, introducing the recombinant expression vector obtained in the step S3 into escherichia coli BL-21 so as to increase the number of the recombinant expression vector; s5, introducing the recombinant expression vector obtained in the step S4 into lactobacillus plantarum C8 to obtain a recombinant strain; and step S6, co-culturing lactobacillus plantarum C8 and the recombinant strain obtained in the step S5. The lactobacillus plantarum C8 has the advantages that the whole lactobacillus plantarum C8 and the recombinant strain have better survival condition and adhesiveness in gastric juice and intestinal juice.

The present invention discloses an antibacterial peptide cecropin A mutant, a recombinant expression vector, a Bacillus subtilis engineering bacterium and applications thereof. By modifying the antibacterial peptide cecropin A, the present invention screened mutants with antibacterial activities superior to those of the original cecropin A, and through the construction of a recombinant expression vector, heterologous expression was carried out using the biosafe strain Bacillus subtilis. Compared with the original antibacterial peptide cecropin A, the antibacterial activities of the mutants of the present invention were increased by 60% and 80% respectively. The present invention uses Bacillus subtilis as a secretion expression system to express the antibacterial peptide cecropin A mutant, which is conducive to large-scale industrial production and cost savings.

The present invention relates to the field of genetic engineering technology, specifically disclosing a raccoon dog interferon-α and β-defensin fusion protein, its encoding gene, and its application. The raccoon dog interferon-α and β-defensin fusion protein has the amino acid sequence shown in SEQ ID NO:1. The present invention also provides a gene encoding the fusion protein, a recombinant expression vector, and a host cell. The fusion protein provided by the present invention possesses the dual biological activities of raccoon dog interferon-α and β-defensin, and has certain antiviral and antibacterial activities.

The present disclosure concerns polypeptide having fumonisin esterase activity exhibiting increased fumonisin esterase activity, when measured at a temperature of at least 37° C., when compared to the control polypeptide comprising the amino acid of SEQ ID NO: 3. The polypeptides of the present disclosure include one or more amino acid variations which contribute to the increase fumonisin esterase activity. The present disclosure also includes compositions comprising the polypeptide having fumonisin esterase activity, methods for detoxifying a fumonisin mycotoxin as well as processes for making the compositions comprising the polypeptide having fumonisin esterase activity.

The invention discloses an aldehyde reductase mutant and application thereof in synthesis of a dexmethylphenidate hydrochloride intermediate, and belongs to the field of molecular biology and enzyme engineering. The aldehyde reductase mutant, polynucleotide for coding the mutant, and the recombinant expression vector can express the aldehyde reductase mutant and are used for constructing a recombinant cell or a recombinant strain for expressing the aldehyde reductase mutant. The provided aldehyde reductase mutant can catalyze 2-phenyl-2-((R)-piperidine-2)-acetaldehyde into (R)-2-phenyl-2-((R)-piperidine-2)-1-ethanol, especially improves the stereoselectivity of (R)-2-phenyl-2-((R)-piperidine-2)-1-ethanol, solves the problems of strict conditions, complex reaction and high cost in the existing synthesis method, and has a wide application prospect in the field of synthesis of (R)-2-phenyl-2-((R)-piperidine-2)-1-ethanol. Wide application prospects are realized.

The invention provides an engineered ketoreductase mutant, which comprises a polypeptide sequence, a gene sequence, a recombinant expression vector containing the gene, an engineering strain, a protein expression method of the engineering strain, and a reaction process for selectively synthesizing (R)-5, 7-difluorochroman-4-ol by using the engineered ketoreductase mutant.

The invention relates to the technical field of biology, in particular to a recombinant fusion protein, polynucleotide for coding the recombinant fusion protein, a recombinant expression plasmid containing the polynucleotide, an engineered recombinant host cell and a method for preparing target polypeptide by using the recombinant fusion protein. The recombinant fusion protein comprises tag polypeptide-target polypeptide-(linker 1-linker x-linker 2-target polypeptide) n from N terminal to C terminal, x is the number of linkers, x is 0 or 1, n is a positive integer not less than 1, the tag polypeptide is SEQ ID NO.1 or SEQ ID NO.2, the linker 1 contains a Kex2 protease enzyme cutting site and a carboxypeptidase B enzyme cutting site, and the linker 1 contains a Kex2 protease enzyme cutting site and a carboxypeptidase B enzyme cutting site. And the connecting peptide 2 contains a WELQ protease enzyme cutting site. The recombinant fusion protein disclosed by the invention is expressed in an inclusion body form, the synthesis process is simplified, the target polypeptide can be prepared with high yield and high purity by using the recombinant fusion protein disclosed by the invention, and the production cost can be reduced from multiple dimensions.

The present application relates to a pyridoxal kinase mutant, a recombinant expression vector and a microbial cell and their applications, and belongs to the technical field of biological catalysis. In order to solve the problem of low product concentration in existing enzyme catalysis, a pyridoxal kinase mutant is provided, the amino acid sequence is selected from the amino acid sequence shown in SEQ ID NO. 1, the lysine at position 229 is mutated to alanine, phenylalanine, methionine, arginine, threonine, histidine, serine, tyrosine, valine, leucine, isoleucine, proline, asparagine, aspartic acid or glutamic acid; the pyridoxal kinase mutant is used for catalyzing pyridoxal to synthesize pyridoxal phosphate, and a recombinant expression vector and a microbial cell can be further formed. The present application has good enzyme activity, high product conversion rate, high concentration of pyridoxal phosphate obtained, and the concentration of the product catalyzed by the wild-type pyridoxal kinase to phosphorylate pyridoxal is obviously improved.

The invention relates to the technical field of gene engineering, in particular to a cucumber salt-tolerant gene CsWRKY2 and application thereof. The invention provides application of a cucumber gene CsWRKY2 as shown in SEQ ID NO.1 in improvement of salt tolerance and stress resistance of plants or cultivation of salt-tolerant transgenic plants. The application comprises the following steps: constructing a recombinant expression vector containing the cucumber gene CsWRKY2 as shown in SEQ ID NO.1, transforming the recombinant expression vector into agrobacterium tumefaciens, and culturing to obtain recombinant bacteria carrying the recombinant expression vector, infecting the plant by using the recombinant bacteria carrying the recombinant expression vector; the cucumber gene CsWRKY2 is constructed into arabidopsis thaliana, so that the salt resistance of transgenic arabidopsis thaliana can be improved, and the salt resistance of cucumber hairy roots can also be improved by infecting the cucumber hairy roots with the cucumber gene CsWRKY2. And a basis is provided for breeding new stress-resistant varieties of arabidopsis thaliana and cucumbers.

The invention discloses a construction method and application of a chlamydomonas reinhardtii-sourced high-sweetness protein variant engineering algal strain, the construction method comprises the following steps: carrying out gene modification on sweeteners Thaumatin and Brazzein, optimizing preference codons of chlamydomonas reinhardtii to synthesize CrThaumatin and CrBrazzein encoding genes, cloning the encoding genes into an expression vector pGM6, introducing the recombinant expression vector into a chlamydomonas reinhardtii wild-type chlamydomonas sp. Algal strain, and carrying out high-sweetness protein variant engineering algal strain of the chlamydomonas reinhardtii-sourced high-sweetness protein variant engineering algal strain of the chlamydomonas reinhardtii. And screening by using a paromomycin resistance marker carried by the expression vector to successfully obtain an engineering algal strain. According to the present invention, the engineering strain is subjected to fermentation production to obtain the dry and stable Chlamydomonas reinhardtii powder rich in the target sweet protein, and the protein purification oral test results show that the sweet taste of the Chlamydomonas reinhardtii powder is 3-5 times of the sweet taste of the natural Thaumatin and Brazzein protein;

The invention relates to a recombinant expression cat interferon-omega gene and a preparation method and application thereof, the nucleotide sequence of the cat interferon-omega gene is as shown in SEQ ID NO.1, and the cat interferon-omega gene is obtained by introducing an Fc fusion fragment to the C terminal and / or N terminal of the natural gene sequence of the cat interferon-omega. XTEN or PAS is introduced to prolong a peptide fragment, and original glycosylation modification sites on a natural sequence are reserved. The method comprises the following steps: cloning a cat interferon-omega gene into an expression vector containing double promoters, further transfecting into a cell, carrying out stable cloning and screening, establishing a high-expression cell strain, and carrying out fermentation culture in a bioreactor. According to the invention, the cat interferon-omega gene is subjected to multiple modification and is efficiently expressed in a CHO-K1GS system, so that the protein yield, the stability and the half-life period are remarkably improved; the obtained fusion protein is high in purity and strong in activity, can obviously enhance immune response and protection effect when being matched with cat vaccines, and is good in safety.

The invention provides a microbial agent as well as a preparation method and application thereof. The microbial agent comprises an artificial strain, namely a bacillus velezensis P43-DegQ strain, which is obtained by carrying out genetic engineering oriented modification on bacillus velezensis XY40-1 serving as an engineering bacterium. The method comprises the following steps: replacing an original promoter of a DegQ gene in bacillus velezensis XY40-1 with a P43 promoter, connecting the DegQ gene in the XY40-1 with a PBE-P43 vector to construct a P43-DegQ recombinant expression vector, and introducing the P43-DegQ recombinant expression vector into the bacillus velezensis to obtain a bacillus velezensis P43-DegQ strain. According to the invention, the yield of the bacillus velezensis abinogen is improved through genetic engineering oriented modification, so that the microbial control effect of a microbial agent containing the strain is improved. A resonance biopesticide suspending agent and a resonance microbial seed coating agent prepared from the microbial agent are subjected to resonance treatment, the effects of plant epidemic disease prevention and control and seed germination are greatly improved compared with the prior art, and the microbial agent has a very strong application prospect.

The invention discloses a sugarcane streak mosaic virus infectious cloning vector as well as a construction method and application thereof, and belongs to the technical field of biology. The recombinant plasmid provided by the invention contains a whole genome of the SCSMV, and the nucleotide sequence of the whole genome is the 771 to 10583 nucleotides of SEQ ID No. 1. The recombinant plasmid disclosed by the invention is obtained by taking a pCB301 vector as a skeleton and then inserting the skeleton into a whole genome of SCSMV, and the recombinant agrobacterium tumefaciens (pCB301-SCSMV infectious clone) prepared by the recombinant plasmid can successfully infect nicotiana benthamiana and has efficient infection ability; the infectious clone of the recombinant expression plasmid prepared from the recombinant plasmid can successfully infect nicotiana benthamiana, has efficient infection ability and can express foreign proteins.

Provided herein are IL- 18 polypeptide prodrugs comprising IL- 18, a half-life extension element, an IL- 18 blocking element and a protease cleavable linker. Also provided herein are pharmacal compositions thereof, as well as nucleic acids, recombinant expression vectors, host cells for making such polypeptide prodrugs. Also disclosed are methods of using the polypeptide prodrugs in the treatment of diseases, conditions and disorders.

The invention relates to an alcohol oxidase mutant and application thereof. Specifically disclosed are a mutant derived from Gloeophyllum trabeum alcohol oxidase (GtrAOX-M2), a nucleic acid encoding the alcohol oxidase mutant, a recombinant expression vector containing the nucleic acid, a recombinant expression transformant containing the recombinant expression vector, a preparation method of a recombinant alcohol oxidase catalyst, and a preparation method of the recombinant alcohol oxidase catalyst. The invention also discloses a method for catalyzing methanol to be oxidized into formaldehyde by using the alcohol oxidase, the alcohol oxidase mutant or the recombinant alcohol oxidase catalyst. The activity of the alcohol oxidase mutant provided by the invention is obviously improved compared with that of a female parent, and the enzyme is high in activity and can be heterologously expressed in escherichia coli, so that the alcohol oxidase mutant can efficiently oxidize methanol into formaldehyde and oxidize the methanol into formaldehyde by a one-carbon unit biological utilization methanol enzyme method; wide application prospects are shown in the aspect of subsequent conversion and generation of polyhydric alcohols.

The invention relates to heparinase III with high activity on 6-sulfated heparin and application of the heparinase III. The amino acid sequence of the heparinase III (BeHepIII) is as shown in SEQ ID NO. 2, and the nucleotide sequence of the coding gene is as shown in SEQ ID NO. 1. The invention discovers and discloses a novel heparinase III (BeHepIII) for the first time, the heparinase III is derived from Bacteroides eggerthii, has a higher recombinant expression level in escherichia coli, has very high degradation activity on heparin containing a 6-site sulfated structure, and particularly has the enzyme activity which is 93.5 times of that of commercialized heparinase FhHepIII at present, and the heparinase III can be used for degrading heparin containing 6-site sulfated structure. Therefore, the heparinase III (BeHepIII) provided by the invention has a wide application potential in heparin degradation. In addition, by using heparinase III (BeHepIII), directional excision of a reducing end of heparin oligosaccharide synthesized by a chemical enzyme method is realized, and complete chemical enzyme method synthesis of a pentasaccharide structure with anticoagulant factor Xa activity is successfully realized.

The invention discloses a bispecific antibody which comprises a first protein functional region targeting CD30 and a second protein functional region targeting CD16a, the first protein functional region comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3, and the light chain variable region comprises LCDR1, LCDR2 and LCDR3. The invention also discloses nucleic acid for coding the antibody, a recombinant expression vector, a transformant, a preparation method of the antibody, an antibody drug conjugate, a pharmaceutical composition or a kit containing the antibody drug conjugate, and applications of the nucleic acid, the recombinant expression vector and the transformant in preparation of drugs for preventing and / or treating tumors. The bispecific antibody provided by the invention can effectively activate the NK cells and can effectively target human tumor cell related antigen CD30 protein, mediate the killing activity of the NK cells to target cells, and induce and further enhance the tumor inhibition effect of the NK cells to tumor cells.

The invention belongs to the technical field of plant genetic engineering, and particularly relates to application of an AhHTF1 gene in improving high temperature resistance of plants. The nucleotide sequence of the AhHTF1 gene is shown as SEQ ID NO.1. According to the invention, a recombinant expression vector pCAMBIA1307-AhHTF1 is constructed, and the recombinant expression vector is introduced into a model plant tobacco, so that a transgenic tobacco plant over-expressing the AhHTF1 is obtained. A high-temperature stress treatment experiment shows that overexpression of the AhHTF1 gene can improve the tolerance of the plant to high-temperature stress, and the AhHTF1 gene can be used for carrying out genetic improvement on the heat resistance of the plant.

The invention discloses a fusion antibacterial peptide BMAP18-BSN37 and application thereof, and belongs to the technical field of gene engineering. The nucleotide sequence of the fusion antibacterial peptide BMAP18-BSN37 is as shown in SEQ ID NO. 1, and the amino acid sequence of the fusion antibacterial peptide BMAP18-BSN37 is as shown in SEQ ID NO. 2. The fusion antibacterial peptide BMAP18-BSN37 gene is inserted into a pNZ8148 expression vector to construct a recombinant expression vector pUBB, so that protein aggregation or degradation in cells can be avoided, and the survival rate of strains and the stability of protein expression are improved. The method comprises the following steps: transferring a plasmid pUBB into a lactic acid bacteria NZ9000 strain through electrotransformation, and screening a recombinant lactic acid bacteria strain capable of expressing a fusion protein BMAP18-BSN37 to obtain a recombinant strain NZ-BB; the recombinant lactic acid bacteria NZ-BB strain shows a remarkable prevention effect in an animal infection model, and can effectively reduce bacterial colonization and relieve pathological injury; the Salmonella strain has the potential of being used as an animal feed additive, can reduce the use of antibiotics and chemicals, slow down the development of bacterial drug resistance, improve animal immunity and slow down intestinal inflammation caused by salmonella, and provides support for effectively preventing the health of livestock and poultry.

The present invention relates to: a receptor tyrosine kinase like orphan receptor 1 (ROR 1) antibody or an antigen-binding fragment thereof; a nucleic acid encoding same; a recombinant expression vector carrying the nucleic acid; a host cell transinfected with the recombinant expression vector; a method for preparing the antibody or the antigen-binding fragment thereof; a bi- or multi-specific antibody bearing the antibody or the antigen-binding fragment thereof; an immune cell-engaging bi- or multi-specific antibody; an antibody-drug conjugate (ADC) in which the antibody or the antigen-binding fragment thereof is bound to a drug; a chimeric antigen receptor (CAR) containing the scFv of the antibody as an antigen-binding site of an extracellular domain; an immune cell having the chimeric antigen receptor introduced thereinto; a composition for combination therapy including the antibody or the antigen-binding fragment thereof; a composition for preventing or treating cancer; and a method for preventing or treating cancer.